Wockhardt is currently trading at Rs. 609.75, up by 4.70 points or 0.78% from its previous closing of Rs. 605.05 on the BSE.
The scrip opened at Rs. 614.90 and has touched a high and low of Rs. 615.30 and Rs. 609.00 respectively. So far 21,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1129.00 on 21-Jul-2016 and a 52 week low of Rs. 555.00 on 22-Jun-2017.
Last one week high and low of the scrip stood at Rs. 615.30 and Rs. 579.80 respectively. The current market cap of the company is Rs. 6,732.00 crore.
The promoters holding in the company stood at 74.25%, while Institutions and Non-Institutions held 7.26% and 18.49% respectively.
Wockhardt has received final approval from United States Food and Drug Administration (USFDA) for its ANDA for 0.1% ophthalmic solution of Olopatadine HCI. The eye drop Olopatadine HCI 0.1% ophthalmic solution is a generic version of Patanol, marketed at US by Alcon, a subsidiary of Novartis.
The product will be manufactured at USFDA approved contract manufacturing organization based in Montreal, Canada.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API's, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.